A new study found that Ozempic's main ingredient may treat people with type 1 diabetes, control blood sugar, and lose weight.

Semaglutide, the active ingredient in Ozempic, and other drugs in the same class have revolutionized the treatment of obesity and type 2 diabetes.Now, a clinical trial suggests the medicines can ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

Type 1 and type 2 diabetes both affect how the body handles blood glucose, but they’re quite different in cause and treatment. Type 1 diabetes (T1D) is an autoimmune condition, usually diagnosed ...

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a randomized trial showed.

About 1.9 million people in the United States have type 1 diabetes, including an estimated 244,000 kids and teens, according to the American Diabetes Association. And though type 1 diabetes is ...

A new study finds the use of weight loss drugs like Ozempic, Wegovy, and Zepbound in people with Type-1 Diabetes has risen sharply. It comes even though there's little information on the drugs ...

More people with type 1 diabetes are using GLP-1s like Ozempic and Zepbound, a new study found. Researchers attribute the high demand to rising rates of obesity among people with type 1 diabetes.

A cure for diabetes has been top of mind for many that live with the conditions under the term’s umbrella. But type 1 diabetes, in particular, is an irreversible lifelong autoimmune condition.

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related cancers, especially colorectal cancer, according to data released on ...

Researchers have 3D printed devices made of insulin-producing cells. These devices could enable a long-term treatment for type 1 diabetes that would let people produce their own insulin ...

Parma woman was among the first patients in Northeast Ohio to receive the first FDA-approved drug, Tzield that can delay the onset of Type 1 diabetes and the need for insulin for up to three years.